Month: May 2022

Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates

Written by Customer Service on May 11, 2022. Posted in Earnings Releases And Operating Results.

– Presented Preclinical Data at AACR Annual Meeting Supporting Clinical Development of MRT-2359 as Potent and Selective GSPT1-directed Molecular Glue Degrader in Solid Tumors; Company on Track to File Investigational New Drug (IND) Application Mid-year – – Initiated Research with École Polytechnique Fédérale de Lausanne (EPFL); Collaboration to Broaden Monte Rosa’s AI Capabilities – BOSTON, May 11, 2022 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today reported business highlights and financial results for the first quarter, ended March 31, 2022. “Our first quarter was marked by exciting progress across our pipeline of molecular glue degraders and our proprietary QuEEN™ platform,” said Markus Warmuth, M.D., CEO of Monte...

Minim Reports 27% Sequential Growth in First Quarter 2022 Revenue to $13.3 Million

Written by Customer Service on May 11, 2022. Posted in Earnings Releases And Operating Results.

#1 in Market Share Position for Cable Modems and Gateways on Amazon for Q1 2022 MANCHESTER, NH, May 11, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Minim, Inc. (NASDAQ: MINM), the creator of intelligent WiFi software and Motorola home networking products under an exclusive global brand license, today reported first quarter financial results for the period ended March 31, 2022. Q1 2022 Financial Highlights:Net revenue of $13.3 million, up 27% quarter-over-quarter compared to $10.5 million in Q4 2021. Total deferred revenue as of March 31, 2022 increased by 13% compared to Q4 2021. Gross margin of 31.5% compared to 33.0% in Q4 2021. Net loss of ($2.5) million compared to a net loss of ($3.2) million in Q4 2021. Accounts payable declined to $8.2 million compared to $12.5 million at the end of the prior quarter.Recent...

MasterCraft Boat Holdings, Inc. Reports Record Results for Fiscal 2022 Third Quarter

Written by Customer Service on May 11, 2022. Posted in Earnings Releases And Operating Results.

VONORE, Tenn., May 11, 2022 (GLOBE NEWSWIRE) — MasterCraft Boat Holdings, Inc. (NASDAQ: MCFT) today announced financial results for its fiscal 2022 third quarter ended April 3, 2022. Highlights:Delivered the most profitable quarter in the Company’s history; the sixth consecutive record-setting quarter. Net sales for the third quarter increased to $186.7 million, up 26.3% from the prior-year period. Net income was $20.9 million, up 19.2%. Diluted Net Income per share was $1.13, up 21.5%. Diluted Adjusted Net Income per share, a non-GAAP measure, was $1.21, up 19.8%. Adjusted EBITDA, a non-GAAP measure, increased to $32.1 million, up 16.4%. Share repurchases of $10.1 million during the quarter.Fred Brightbill, Chief Executive Officer and Chairman, commented, “Once again, our business performed extremely well during the third...

Pipestone Energy Corp. Reports First Quarter 2022 Results and Provides an Operations Update

Written by Customer Service on May 11, 2022. Posted in Earnings Releases And Operating Results.

Figure 1 Pipestone development mapFigure 2 Three-Year Corporate PlanCALGARY, Alberta, May 11, 2022 (GLOBE NEWSWIRE) — (PIPE – TSX) Pipestone Energy Corp. (“Pipestone” or the “Company”) is pleased to report its first quarter 2022 financial and operational results, and to provide an update on its operations, including the encouraging early results from the flowback of its 12-36 eastern exploration well. FIRST QUARTER 2022 CORPORATE HIGHLIGHTS:The Company generated record revenue of $153.5 million, which more than doubled Q1 2021 revenue of $71.5 million, and represents a 12% increase from Q4 2021 revenue of $137.3 million; In Q1 2022, Pipestone achieved average quarterly production totaling 27,581 boe/d (29% condensate, 43% total liquids), representing a 28% quarterly increase over Q1 2021 production of 21,595 boe/d. Production...

Aspira Women’s Health Reports First Quarter 2022 Financial Results

Written by Customer Service on May 11, 2022. Posted in Earnings Releases And Operating Results.

Product Revenue Increased 30% to $1.8 million; OVA1plus Volume Grew 28% to 4,819 Units New Ordering Physicians in the First Quarter Grew 47% to 603 Year Over Year Board and Leadership appointments announced Conference Call and Webcast scheduled for today, May 11th at 8:30 a.m. ET AUSTIN, Texas, May 11, 2022 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the first quarter ended March 31, 2022. “We are pleased to announce our first quarter 2022 results. Strong commercial performance – especially the trend in new ordering physicians – should set the stage for commercial success for the rest of the year,” said Nicole Sandford, Aspira’s President and Chief Executive Officer. “We are also...

NevGold Begins Trading on The OTCQX Best Market

Written by Customer Service on May 11, 2022. Posted in Public Companies.

Vancouver, British Columbia, May 11, 2022 (GLOBE NEWSWIRE) — NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce that its shares have qualified for trading on the OTCQX®Best Market (the “OTCQX”). Trading will continue under the symbol “NAUFF” on the OTCQX. NevGold CEO, Brandon Bonifacio, comments: “The upgrade to the OTCQX enables our U.S. shareholders to more effectively participate in trading NevGold shares and will enhance liquidity. With extremely promising, high-grade oxide gold drill results from our Limousine Butte Project in Nevada, we have attracted many U.S.-based retail and institutional investors who are interested in exposure to gold resource development and exploration within the United States. We have many further drillholes at the assay lab, and we look forward...

Iterum Therapeutics Provides Regulatory Update

Written by Customer Service on May 11, 2022. Posted in Public Companies.

DUBLIN, Ireland and CHICAGO, May 11, 2022 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced it met with the US Food and Drug Administration (“FDA”) on May 5, 2022, to discuss its proposed plan to conduct one additional Phase 3 clinical trial to support the potential resubmission of the Company’s new drug application (“NDA”) for oral sulopenem etzadroxil-probenecid (“oral sulopenem”) for the treatment of uncomplicated urinary tract infections (“uUTI”). “We are pleased to announce that we have reached general alignment with the FDA on key aspects of our proposed trial design to support...

Arqit Quantum Inc. Announces Independent Assurance Report on its Technology

Written by Customer Service on May 11, 2022. Posted in Public Companies.

Independent review of Arqit’s security proof confirms QuantumCloud™ to be “a significant advance in secure communications” LONDON, May 11, 2022 (GLOBE NEWSWIRE) — Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (“Arqit”), a global leader in quantum encryption technology, today announced the completion of an independent assurance report undertaken by University of Surrey on the technology protocols used by Arqit to enable symmetric key agreement over classical IP network infrastructures. The independent assurance report confirms the security proof of Arqit’s customer end point symmetric key agreement software in that it creates keys which are zero trust and computationally secure. This work builds upon a technical review by University of Surrey which used a well-established Tamarin cryptographical modelling tool to validate the...

Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference

Written by Customer Service on May 11, 2022. Posted in Public Companies.

FARMINGTON HILLS, Mich., May 11, 2022 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced presentations by Mina Sooch, Founder and CEO, at the New Pathways in Retinal Diseases Panel at Retina World Congress (RWC) on May 12, 2022 and at H.C. Wainwright Global Investment Conference on May 24, 2022. Dr. David Lally will also be presenting masked safety data from Phase 2b APX3330 trial at RWC and Clinical Trials at the Summit on May 21, 2022.Retina World Congress – May 12-15, 2022Session: New Pathways in Retinal DiseasesPresenter: Mina Sooch, MBA, President and CEODate: Thursday, May 12, 2022Time: 10:20-11:00 AM EDTLocation: Marriott...

Neuronetics Files Federal Lawsuit Against Brainsway for Misleading Psychiatrists and Patients

Written by Customer Service on May 11, 2022. Posted in Public Companies.

MALVERN, Pa., May 11, 2022 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the filing of a federal lawsuit in the District of Delaware against Brainsway Ltd. and Brainsway USA Inc. for unfair competition under the Lanham Act and state law. In the litigation, the Company asserts that, for commercial gain, Brainsway egregiously misrepresented efficacy data for the treatment of anxious depression with NeuroStar Advanced Therapy for Mental Health. Specifically, the Company argues that Brainsway manipulated NeuroStar’s effect size by presenting an endpoint representing an incomplete course of therapy. Brainsway then compared these...

Month: May 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals